Clinical trial risk in Non-Hodgkin's lymphoma: Endpoint and target selection

Journal of Pharmacy and Pharmaceutical Sciences

Volumn 14, Issue 2, 2011, Pages 227-235

  Parker, Jayson L ^a   Zhang, Zoe Yi ^a   Buckstein, Rena ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; FLUDARABINE; NEW DRUG; PENTOSTATIN; PIXANTRONE; PREDNISONE; RITUXIMAB; VINCRISTINE; VORINOSTAT;

ARTICLE; CANCER CLASSIFICATION; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; DRUG EFFICACY; DRUG SCREENING; DRUG TARGETING; DRUG TREATMENT FAILURE; HUMAN; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; STUDY DESIGN;

EID: 79959315593     PISSN: None     EISSN: 14821826     Source Type: Journal    
DOI: 10.18433/j39p45     Document Type: Article

References (29)

1. Rekhert JM, Wenger JB. Development trends for new cancer therapeutics and vaccines. Drug Discov Today 13:30-37, 2008.
2. US Food and Drug Administration. Challenge and opportunity on the critical path to new medical products.http://www.fda.gov/oc/initiatives/criticalpath/whitepaper.pdf, Retrieved on 2009-01-25, 2004.
3. Kaitin KI, DiMasi JA. Pharmaceutical innovation in the 21st century: New drug approvals in the first decade 2000-2009. Clinical Pharmacology & Therapeutics 89(2): 183-188. 2011.
4. DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: New estimates of drug development costs. J. Health Econ 22:151-185, 2003.
5. Adams CP, Brantner W: New drug development: Estimating entry from human clinical trials. FTC Working Paper No. 262 262, 2003.
6. Honig P and Lalonde R. The economics of drug development: a grim reality and role of clinical pharmacology. Clinical Pharmacology and Therapeutics 87 (3): 247-251. 2010.
7. Adams CP, Van Brantner V: Market watch : Estimating the cost of new drug development: Is it really $802 million? Health Aff 25:420-428, 2006.
8. DiMasi JA, Grabowski HG, Vernon J: R&D costs and returns by therapeutic category. Drug Inf J 38:211-223, 2004.
9. Munos B. Lessons from 60 years of pharmaceutical innovation. Nature Reviews Drug Discovery 8: 959-968. 2009.
10. World Health Organization. The world medicines situation. 2004.
11. Parker JL and J. Clare Kohler. The success rate of new drug development in clinical trials: Crohn's disease. J Pharm Pharm Sci, 13(2): 191-197, 2010.
12. US Food and Drug Administration. Guidance for industry: clinical trial endpoints for the approval of cancer drugs and biologics. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), 2007.
13. Cheson BD, Horning SJ, Coiffier B, et al: Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 17:1244-1253, 1999.
14. Cheson BD, Pfistner B, Juweid ME, et al: Revised Response Criteria for Malignant Lymphoma. J Clin Oncol 25:579-586, 2007.
15. st2010.http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareD.rovalApplications/TherapeuticBiologicApplications/ucm113522.htm
16. National Cancer Institute. Definition of targeted therapy - NCI Dictionary of Cancer Terms. http://www.cancer.gov/Templates/db_alpha.aspx?CdrID=270742. Retrieved on 2009-01-25, 2009.
17. Feugier P, Van Hoof A, Sebban C, et al: Long-Term Results of the R-CHOP Study in the Treatment of Elderly Patients With Diffuse Large B-Cell Lymphoma: A Study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 23:4117-4126, 2005.
18. Pfreundschuh M, Truper L, Oterborg A, et al. CHOPlike chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with goodprognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 7:379-391, 2006.
19. Duvic M, Talpur R, Ni X, et al. Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 109:31-39, 2007.
20. Olsen EA, Kim YH, Kuzel TM, et al. Phase IIB Multicenter Trial of Vorinostat in Patients With Persistent, Progressive, or Treatment Refractory Cutaneous T-Cell Lymphoma. J Clin Oncol 25:3109-3115, 2007.
21. Kane RC, Dagher R, Farrell A, et al. Bortezomib for the Treatment of Mantle Cell Lymphoma. Clin Cancer Res 13:5291-5294, 2007.
22. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 16:2825-2833, 1998.
23. J.A. DiMasi, L. Feldman and A. Wilson. Trends in risks associated with new drug development: success rates for investigational drugs. J Clin Pharm and Ther. 87(3):272-277, 2010.
24. DiMasi, L. Feldman and A. Wilson. Trends in risks associated with new drug development: success rates for investigational drugs. Clin Pharmacol Ther. 87(3):272-277, 2010.
25. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 3:711-715, (2004)
26. Emanuel EJ, Schnipper LE, Kamin DY, et al: The Costs of Conducting Clinical Research. J Clin Oncol 21:4145-4150, 2003.
27. Roberts TG, Jr., Lynch TJ, Jr., Chabner BA. The Phase III Trial in the Era of Targeted Therapy: Unraveling the Go or No Go Decision. J Clin Oncol 21:3683-3695, 2003.
28. Stanley, K. Design of randomized controlled trials. Circulation 115(9): 1164-1169. 2007.
29. Hurvitz, S. A. Evolving options for the treatment of metastatic breast cancer: Progression-free survival as an endpoint. Cancer Treat Rev. Feb 9, 2011.